The beneficial effects of treatment with beta-blockers in patients with chronic heart failure have been demonstrated in several large, prospective, randomised, placebo-controlled clinical trials. In large trials with mortality as the end-point, the long-term use of bisoprolol, carvedilol, nevibolol and metoprolol succinate have been associated with a reduction In total mortality, cardiovascular mortality, sudden cardiac death and death due to progression of heart failure in patients of functional classes II-IV These favorable clinical experiences warrant a recommendation that beta-blockers should be used in all haemodynamically stable heart failure patients with reduced left ventricular systolic function who are on standard treatment, unless contraindicated. In this review, the most important data of clinical trials and practical considerations of therapy with beta-blockers in heart failure are summarized.
|Translated title of the contribution||The use of beta receptor blockers in chronic heart failure|
|Number of pages||4|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Jul 1 2007|
ASJC Scopus subject areas